Superworth

Revvity RVTY

Medical - Diagnostics & Research, Healthcare
$151.65
−3.41%
Market cap
$16.9B
PE
72.2×
10y median 35.1×
Forward PE
n/m
not a meaningful number
Price to sales
5.8×
EV/EBIT
44.2×
Revenue, 12 months
$2.9B
+4% on a year ago
Net margin
8.2%
Free cash flow yield
3.3%

Revvity trades at 72.2× trailing earnings, pricier than 90% of the last ten years. Revenue was $2.9B over the last twelve months, up 4% on a year earlier with a 8% net margin.

Charts

Financials

Income statement for RVTY, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$670.7M−6%$695.9M−6%$649.9M−4%$691.7M−3%$684M+2%$729.4M+5%$664.8M+2%$720.3M+4%$698.9M+2%$772.1M+6%$711.1M+7%$729.7M+1%
Cost of revenue$298.2M−2%$312.4M+3%$294.9M+1%$306.2M−0%$299.2M+0%$317.1M+2%$289.2M−2%$327.7M+7%$324.3M+8%$350.4M+11%$323.5M+12%$312.8M−5%
Gross profit$372.5M−9%$383.5M−12%$355M−7%$385.5M−4%$384.8M+3%$412.3M+8%$375.5M+6%$392.6M+2%$374.6M−3%$421.7M+2%$387.7M+3%$416.9M+6%
R&D$53M−1%$49.6M−9%$50.4M−11%$48.1M−16%$49.1M−7%$49.2M−1%$53.6M+6%$53.3M+11%$50.8M+3%$58.2M+18%$57.9M+8%$49M−8%
SG&A$250.2M+3%$256.7M+5%$260.6M+5%$251.7M−6%$237.5M−5%$244.3M−5%$249.7M−4%$248.5M−1%$241.9M+2%$251.7M+3%$253.9M+2%$278.6M+12%
$69.2M−38%$77.2M−44%$44.1M−42%$85.7M+10%$98.2M+42%$118.8M+54%$72.2M+64%$90.8M+6%$81.9M−17%$111.7M−6%$75.9M+5%$89.3M−2%
Interest expense$25.5M−2%$24.6M+9%$24.4M+7%$24.7M−5%$24.4M−4%$22.8M−7%$23M−6%$22.9M−7%$22.8M−7%$23.5M+3%$24.7M+8%$23M+0%
Pre-tax income$50.6M−38%$31.4M−77%$34.5M+17%$86.7M+21%$100.4M+98%$94.6M+201%$52.4M+52%$68.7M−21%$55.7M−45%$91.6M−3%$50M−5%$63.5M−8%
$18.1M+44%−$32.2M$5.9M+27%$14.1M+9%$7M−62%$6.2M$10.7M+83%$13.4M−5%$8.5M+21%−$4.2M$9.1M−15%$10.1M−25%
Net income$9.5M−89%$78.6M−39%$26M−95%$55.4M+56%$94.4M+894%$94.6M+21%$42.2M+62%$53.9M−3%$46.7M−51%$98.4M+4%$40.7M−4%$51.8M−4%
$0.08−88%$0.64−37%$0.21−95%$0.45+61%$0.77+863%$0.78+22%$0.35+67%$0.46+2%$0.40−48%$0.87+12%$0.36+3%$0.47+2%
124.2M−2%123.2M−2%123.5M−2%123.5M−2%123M−1%121.3M−2%120.2M−3%117.5M−5%115.5M−6%113.2M−7%111.9M−7%111.6M−5%

Gross profit: 69 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: Q4 FY09 and Q4 FY10: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 8 periods, Q3 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 3 periods, Q4 FY11 to Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 12 periods, Q4 FY13 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Diagnostics & Research nearest Revvity's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
RVTYRevvity$16.9B72.2×35.1×n/m5.8×+4%8.2%
MEDPMedpace$18.1B38.0×34.5×n/m6.5×+25%17.7%
DGXQuest Diagnostics$27.5B24.9×19.3×n/m2.3×+9%9.5%
LHLabcorp$28.9B29.4×19.5×18.8×2.0×+6%7.0%
BIOBio-Rad Laboratories$9.8B44.4×30.9×n/m3.8×+1%8.6%
CAICaris Life Sciences$9.1B86.8×78.4×n/m9.2×+85%10.6%
MTDMettler-Toledo International$34.2B38.4×36.6×34.6×8.3×+7%21.9%
ILMNIllumina$35.7B44.0×51.3×41.5×8.0×+5%18.4%
IQVIQVIA$42.5B32.0×34.8×19.0×2.5×+8%8.1%
LNTHLantheus$6.5B24.3×24.0×n/m4.2×+2%17.7%
WATWaters$46.4B118×29.2×30.4×10.0×+52%3.6%
Peer median$28.2B38.2×32.7×30.4×5.4×+8%10.1%

More on Revvity

Each number over time

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .